Takeda’s dengue vaccine proves efficacious in massive Phase 3 trial

pharmafile | January 30, 2019 | News story | Research and Development Dengue fever, TAK-003, Takeda, Vaccine, dengue, health, infectious diseases 

Takeda’s dengue vaccine candidate TAK-003, has proved efficacious in preventing dengue fever in healthy children and adolescents in an ongoing Phase 3 trial.

The tetravalent vaccine, which was found to be well tolerated, met its primary efficacy endpoint in a pivotal Phase 3 trial.

“We are very encouraged by the performance of our dengue vaccine candidate in the study. This brings us one step closer to helping the world tackle the massive burden of dengue,” said Dr Rajeev Venkayya, President of the Global Vaccine Business Unit at Takeda.

“We are excited to publish the data in a peer-reviewed journal as quickly as possible. In parallel, we are advancing the clinical development, commercial manufacturing, and stakeholder consultations to support a potential future global launch of the vaccine.”

The trial enrolled 20,000 healthy children and adolescents between the ages of four and 16, who were living in dengue-endemic areas.

The Japanese firm is also working on vaccines for other highly infectious including Zika, norovirus and polio.   

Louis Goss

Related Content


GSK’s RSV vaccine approved in EU for older adults

GSK has announced that the European Commission (EC) has authorised Arexvy, the company’s respiratory syncytial …

FDA approves Pfizer’s RSV vaccine for older adults

Global pharmaceutical company Pfizer has announced that the US Food and Drug Administration (FDA) has …


FDA committee votes in favour of Pfizer’s RSV vaccine for maternal immunisation

Pfizer has announced that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) from the …

Latest content